Altered endocannabinoid-dynamics in craniopharyngioma patients and their association with HPA-axis disturbances

Matthias K Auer, Dorothea Gebert, Sarah V Biedermann, Laura Bindila, Günter Stalla, Nicole Reisch, Anna Kopczak, Johannes Fuss. Eur J Endocrinol. 2021 Jul 1;185(2):231-239.

Observational studyHumans

Design

Observational study

Subjects

18 patients with craniopharyngioma and 16 age- and sex-matched controls

Dose used in the study

Not applicable; palmitoylethanolamide was measured, not given

Duration

Single session with endurance exercise

What was measured

Blood 2-AG, anandamide, oleoylethanolamide, palmitoylethanolamide and arachidonic acid at rest and after exercise, with ACTH, cortisol and copeptin.

What the authors reported

This observational study found:

• Resting 2-AG was more than twice as high in patients as in controls.
• Exercise raised 2-AG and oleoylethanolamide in controls but not in patients.
• HPA measures did not explain 2-AG differences.
• The abstract reports no group difference or exercise change for palmitoylethanolamide.

Limits of this study

A small cross-sectional study of one centre; it measured PEA levels and did not test PEA treatment. No PEA-specific result is given in the abstract. Funding and conflicts not stated in the abstract.

Source

PubMed 34061772 · doi:10.1530/EJE-21-0178

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.